Mitophagy: The Cellular Cleanup System Driving Disease and Longevity Therapies
A comprehensive 2026 review reveals how mitochondrial self-cleaning gone wrong underlies neurodegeneration, heart disease, cancer, and aging.
Summary
This landmark 2026 review from EPFL and Fudan University synthesizes decades of research on mitophagy — the selective autophagy pathway that eliminates damaged mitochondria. The authors detail the molecular machinery of the PINK1–Parkin ubiquitin-dependent pathway and receptor-mediated pathways, explaining how 'eat me' signals recruit autophagy machinery for lysosomal degradation. They show that dysregulated mitophagy is a unifying feature across neurodegenerative diseases (Parkinson's, Alzheimer's), cardiovascular disease, metabolic disorders, immune dysfunction, and cancer. The review maps emerging therapeutic strategies — from small-molecule mitophagy activators to precision targeting of specific pathway components — positioning mitophagy restoration as a broad translational opportunity for human health and longevity.
Detailed Summary
Mitochondria are far more than energy factories — they coordinate fatty acid metabolism, calcium homeostasis, ROS signaling, innate immunity, and cell death. Maintaining mitochondrial integrity is therefore essential not just for individual cells but for tissue and organismal health. Mitophagy, the selective autophagic clearance of damaged mitochondria, is the primary mechanism by which cells enforce this integrity, and its dysregulation is now recognized as a shared driver of aging and a remarkably broad spectrum of diseases.
This comprehensive 2026 review from Wang, Sun, Li, and Auwerx provides the most up-to-date synthesis of mitophagy mechanisms, disease connections, and therapeutic opportunities. The authors systematically dissect the two major mitophagy pathways. In the PINK1–Parkin ubiquitin-dependent pathway, mitochondrial depolarization prevents PINK1 import and degradation, causing PINK1 to accumulate on the outer mitochondrial membrane (OMM), dimerize, and trans-autophosphorylate. Activated PINK1 phosphorylates ubiquitin at Ser65, recruiting and activating the E3 ligase Parkin, which decorates OMM proteins with polyubiquitin chains in a powerful feedforward amplification loop. Selective autophagy receptors — particularly OPTN and NDP52 — then bridge ubiquitinated mitochondria to the autophagy initiation machinery, with TBK1 kinase further amplifying receptor activity. Receptor-mediated pathways (BNIP3, NIX, FUNDC1, FKBP8, and others) operate independently of ubiquitin, directly engaging LC3/GABARAP proteins on autophagosomes, and are especially important during hypoxia, developmental mitochondrial remodeling (e.g., reticulocyte maturation), and tissue-specific homeostasis.
A key insight of the review is that PINK1–Parkin mitophagy, while dominant in cell-culture models, is largely dispensable for basal mitophagy in most tissues in vivo — demonstrated elegantly by mito-QC reporter mouse and Drosophila studies — suggesting that multiple parallel pathways maintain mitochondrial quality in a context-dependent manner. The review also highlights emerging clearance mechanisms beyond classical macroautophagy, including mitochondria-derived vesicles (MDVs), VDIMs, SPOTs, and mitocytosis.
Disease coverage is extensive. In neurodegeneration, impaired mitophagy allows accumulation of dysfunctional mitochondria and mtDNA, fueling ROS, neuroinflammation, and proteotoxicity in Parkinson's, Alzheimer's, ALS, and Huntington's disease. In cardiovascular disease, both insufficient and excessive mitophagy contribute to ischemia-reperfusion injury, heart failure, and cardiomyopathy. In metabolic disease, mitophagy defects impair pancreatic beta-cell function, hepatic lipid metabolism, and adipose tissue remodeling, linking the pathway to type 2 diabetes and MASLD. Cancer presents a dual role: mitophagy can suppress tumor initiation by limiting mtDNA-driven inflammation, yet established tumors co-opt it for survival under hypoxia and therapeutic stress. Immune cells rely on mitophagy to prevent mtDNA-triggered cGAS–STING and NLRP3 inflammasome activation.
Therapeutically, the authors catalog small molecules targeting PINK1, Parkin, USP30 (a deubiquitinase that antagonizes mitophagy), and receptor-mediated pathways, alongside NAD+ precursors, urolithin A, spermidine, and exercise as physiological mitophagy inducers with promising preclinical and early clinical data. Key challenges include tissue-specific effects, the context-dependency of mitophagy's role (protective vs. harmful), and the absence of validated biomarkers for clinical trials.
Key Findings
- PINK1–Parkin pathway is essential for stress-induced mitophagy but largely dispensable for basal mitophagy in most tissues in vivo.
- Selective autophagy receptors OPTN and NDP52 — not p62 — are the critical drivers of autophagosome recruitment to ubiquitinated mitochondria.
- Mitophagy dysregulation is a unifying mechanism across neurodegeneration, heart failure, metabolic disease, immune disorders, and cancer.
- mtDNA released from damaged mitochondria activates cGAS–STING and NLRP3 inflammasome, linking impaired mitophagy to chronic inflammation.
- NAD+ precursors, urolithin A, spermidine, and USP30 inhibitors represent promising mitophagy-activating therapeutic strategies with early clinical evidence.
Methodology
This is a comprehensive narrative review drawing on the full primary literature through 2025. The authors integrate mechanistic cell biology, mouse and Drosophila genetic models (including mito-QC and mt-Keima reporter systems), and translational/clinical data across multiple disease areas.
Study Limitations
As a review, no new experimental data are generated; conclusions depend on the quality and reproducibility of cited studies. The dual role of mitophagy (protective vs. harmful depending on context) complicates therapeutic targeting. Most mechanistic insights derive from cell culture or model organisms, and translation to human tissues remains incompletely validated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.